Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase II data of cediranib plus fulvestrant in metastatic breast cancer disclosed

Dec. 18, 2009

FOV-2304 prevents retinal edema and inflammation in rat model of diabetic retinopathy

Dec. 18, 2009

Vorinostat in combination with tamoxifen safe and effective in phase II breast cancer trial

Dec. 17, 2009

Pilot trial data indicate beneficial effects of Copaxone in dry AMD

Dec. 17, 2009

Clinical data on candesartan in diabetic retinopathy disclosed at ISOPT

Dec. 17, 2009

Preliminary phase I safety and efficacy of IMGN-901 seen in pretreated MM patients

Dec. 17, 2009

Romiplostim safe and effective in phase I/II study in pediatric ITP patients

Dec. 17, 2009

Final data reported from phase Ib trial of atacicept in pretreated CLL patients

Dec. 17, 2009

Beneficial effects of SUN-11031 in COPD patients with cachexia reported

Dec. 16, 2009

Studies find benefit with intravitreal dexamethasone implant in ocular indications

Dec. 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...